Clinical Trial Update: Managed Access Programs for CTL019, Tisagenlecleucel

View source ↗

Summary

Novartis’ CAR-T therapy tisagenlecleucel (CTL019) is the subject of a clinical trial update focused on managed access programs, including lymphoma and leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Tisagenlecleucel (CTL019) (tisagenlecleucel)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lymphoma, Leukemia | Status: AVAILABLE